| UF | film unsharpness; ultrafiltrate; ultrafiltration; ultrafine; ultrasonic frequency; universal feeder;... |
|---|---|
| PEN | pharmacy equivalent name |
| Pen | penicillin |
| SHORT, S-H-O-R-T | short stature, hyperextensibility of joints or hernia or both, ocular depression, Rieger anomaly, te... |
| short-FRAME | short stature-facial anomalies-Rieger anomaly-midline anomalies-enamel defects [syndrome] |
| glycogen storage disease type III | <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system). The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent. Inheritance: autosomal recessive (12 Dec 1998) |
|---|---|
| grade III astrocytoma | <tumour> Astrocytoma of intermediate grade. See: glioblastoma multiforme. (05 Mar 2000) |
| group III mycobacteria | Mycobacteria that are either colourless or that slowly produce a light yellow pigment when grown in the presence of light. Organisms placed in this group belong to the species Mycobacterium intracellulare. Synonym: nonchromogens. (05 Mar 2000) |
| RNA polymerase III | <enzyme> A DNA-dependent RNA polymerase present in bacterial, plant, and animal cells. It functions in the nucleoplasmic structure where it transcribes DNA into RNA. It has specific requirements for cations and salt and has shown an intermediate sensitivity to alpha-amanitin in comparison to RNA polymerase I and II. Registry number: EC 2.7.7.- (12 Dec 1998) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| class III | All other perennial streams not meeting higher class criteria. (05 Dec 1998) |
| class III antigens | Non-cell membrane molecules that are encoded by the S region of the major histocompatibility complex. These antigens are not involved in determining histocompatibility and include the complement proteins. (05 Mar 2000) |
| class III malocclusion | <dentistry> A Malocclusion where your lower teeth stick out past your upper teeth. This is also called an underbite. (05 Mar 2000) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trials, phase III | Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries. (12 Dec 1998) |
| mucolipidosis III | <biochemistry> Mucolipidosis with mild Hurler-like symptoms, restricted joint mobility, short stature, mild mental retardation, and dysplastic skeletal changes, especially of the hip. Aortic and mitral valve disease are often present. It is associated with a deficiency of UDP-N-acetyl glucosamine and lysosomal enzyme N-acetylglucosaminyl-1-phosphotransferase. Inheritance: autosomal recessive. Synonym: pseudo-Hurler polydystrophy, pseudopolydystrophy. (05 Mar 2000) |
| mucopolysaccharidosis III | Mucopolysaccharidosis characterised by heparitin sulfate in the urine, progressive mental retardation, mild dwarfism, and other skeletal disorders. There are four clinically indistinguishable but biochemically distinct forms, each due to a deficiency of a different enzyme. (12 Dec 1998) |
| congenital antithrombin III deficiency | Antithrombin III is a protein which stimulates the removal of blood clots in the bloodstream. Small blood clots form normally within the bloodstream, but are normally dissolved via the bodys antithrombin III. The deficiency of antithrombin III will result in an increased risk for blood clot formation causing organ damage. This is an inherited as a autosomal dominant trait. Inheritance: autosomal dominant. (27 Sep 1997) |
| connective tissue activating peptide III | Cytokine, produced from platelet basic protein, that acts as a growth factor. (18 Nov 1997) |
| mycinamicin III O-methyltransferase | <enzyme> Catalyses the incorporation of the methyl group of s-adenosyl-l-methionine at the 3'' position of mycinamicin III; from micromonospora griseorubida; genbank d16097 Registry number: EC 2.1.1.- Synonym: mycf gene product, miii o-mtase (26 Jun 1999) |